The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment
Opioid agonist therapies (OAT) to treat opioid addiction in people who inject drugs (PWID) began in Ukraine in 2004. Scale-...
Scaling-up Antiretroviral Therapy in Malawi
In Malawi, health-system constraints meant that only a fraction of people infected with human immunodeficiency virus (HIV) and in immediate need of...
Understanding the Role of Accredited Drug Dispensing Outlets in Tanzania’s Health System
In Tanzania, a public-private partnership launched in 2003 used an accreditation approach to improve access to quality medicines and pharmaceutical...
The Quality of Selected Essential Medicines Sold in Accredited Drug Dispensing Outlets and Pharmacies in Tanzania
The purpose of this study was to investigate the quality of a select group of medicines sold in accredited drug dispensing outlets (ADDOs) and phar...
Strong Health Systems Save Lives, Vol. 5, 2016
On the Front Lines of the Global Fight against TB: Eight Years of Field Research from MSH
Last year, tuberculosis (TB) killed more people than did HIV and AIDS—becoming the world’s deadliest single infectious agent. More than 95 perce...
Fact Sheet: HEAL TB - Curing TB, Saving Lives 2011-2016
While TB is a national and international priority, Ethiopia’s high TB rates were not declining rapidly in the 2000s. From 2011-16, USAID funded ...
Updating National Essential Medicine Lists: A Step-by-Step Advocacy Guide
Building Capacity in South Africa for the Development of Pharmaceutical Policies, Procedures, and Guidelines
As South Africa moves towards universal health coverage, improving good governance at all levels of the pharmaceutical system is critical. The USAID-f...
The Socioeconomic Impact of Multidrug Resistant Tuberculosis on Patients: Results from Ethiopia, Indonesia and Kazakhstan
Abstract Background One of the main goals of the post-2015 global tuberculosis (TB) strategy is that no families affected by TB face catastrophic cost...